Lyka Labs Limited
NSEI:LYKALABS Stock Report
Lyka Labs Balance Sheet Health
Financial Health criteria checks 2/6 Lyka Labs has a total shareholder equity of ₹682.7M and total debt of ₹587.8M, which brings its debt-to-equity ratio to 86.1%. Its total assets and total liabilities are ₹1.6B and ₹884.6M respectively. Lyka Labs's EBIT is ₹57.5M making its interest coverage ratio 1.8. It has cash and short-term investments of ₹62.9M.
Key information
86.1%
Debt to equity ratio
Interest coverage ratio 1.8x Cash ₹62.92m Equity ₹682.65m Total liabilities ₹884.59m Total assets ₹1.57b
Recent financial health updates
Show all updates
Lyka Labs Limited to Report Q2, 2025 Results on Nov 12, 2024 Oct 23
There's Reason For Concern Over Lyka Labs Limited's (NSE:LYKALABS) Massive 36% Price Jump Aug 22
New minor risk - Share price stability Aug 21
Shareholders May Be More Conservative With Lyka Labs Limited's (NSE:LYKALABS) CEO Compensation For Now Aug 03
Lyka Labs Limited to Report Q1, 2025 Results on Aug 09, 2024 Aug 02
Full year 2024 earnings released: ₹0.79 loss per share (vs ₹4.63 loss in FY 2023) Jul 22
Lyka Labs Limited, Annual General Meeting, Aug 09, 2024 Jul 18
Lyka Labs Limited, Annual General Meeting, Aug 09, 2024 Jul 16
Full year 2024 earnings released: ₹0.79 loss per share (vs ₹4.63 loss in FY 2023) May 22
Lyka Labs Limited to Report Q4, 2024 Results on May 21, 2024 May 12
Getting In Cheap On Lyka Labs Limited (NSE:LYKALABS) Is Unlikely Apr 10
Less than half of directors are independent Feb 22
Third quarter 2024 earnings released: EPS: ₹0.53 (vs ₹3.64 loss in 3Q 2023) Feb 09
Lyka Labs Limited to Report Q3, 2024 Results on Feb 08, 2024 Feb 01
Subdued Growth No Barrier To Lyka Labs Limited's (NSE:LYKALABS) Price Jan 05
We Think Lyka Labs (NSE:LYKALABS) Has A Fair Chunk Of Debt Nov 21
Second quarter 2024 earnings released: ₹0.16 loss per share (vs ₹0.14 loss in 2Q 2023) Nov 03
Lyka Labs Limited to Report Q2, 2024 Results on Nov 02, 2023 Oct 21
Lyka Labs Limited Receives Product Permission from the Central Drugs Standard Control Organization of India to Manufacture and Market Tofacitinib Ointment 2% w/w Oct 12
Lyka Labs Limited Announces Cessation of Sandeep Parikh as Independent Director Sep 27
Lyka Labs Limited to Report Q1, 2024 Results on Aug 02, 2023 Jul 28
Full year 2023 earnings released: ₹4.63 loss per share (vs ₹13.56 profit in FY 2022) Jul 14
Lyka Labs Limited, Annual General Meeting, Aug 02, 2023 Jul 12
Lyka Labs Limited, Annual General Meeting, Aug 02, 2023 Jul 11
These 4 Measures Indicate That Lyka Labs (NSE:LYKALABS) Is Using Debt Extensively Jun 08
Full year 2023 earnings released: ₹4.63 loss per share (vs ₹13.56 profit in FY 2022) May 24
Lyka Labs Limited to Report Q4, 2023 Results on May 23, 2023 May 19
A Look At The Fair Value Of Lyka Labs Limited (NSE:LYKALABS) Mar 15
Third quarter 2023 earnings released: ₹3.64 loss per share (vs ₹2.11 profit in 3Q 2022) Feb 08
Lyka Labs Limited to Report Q3, 2023 Results on Feb 07, 2023 Feb 01
Less than half of directors are independent Nov 16
Second quarter 2023 earnings released: ₹0.14 loss per share (vs ₹9.90 profit in 2Q 2022) Nov 11
Lyka Labs Limited to Report Q2, 2023 Results on Nov 09, 2022 Nov 03
High number of new directors Sep 02
Unpleasant Surprises Could Be In Store For Lyka Labs Limited's (NSE:LYKALABS) Shares Aug 25
Investor sentiment improved over the past week Aug 24 Lyka Labs Limited Announces Board Appointments
Lyka Labs Limited Announces Resignation of Smt. Nehal N. Gandhi as Director with Effect from August 8, 2022 Aug 09
Lyka Labs Limited Announces Cessation of Vinod S. Shanbhag as Independent Director Aug 02
Full year 2022 earnings released: EPS: ₹13.57 (vs ₹4.07 loss in FY 2021) Jul 14
Is Lyka Labs (NSE:LYKALABS) A Risky Investment? Jun 11
Full year 2022 earnings released: EPS: ₹13.57 (vs ₹4.07 loss in FY 2021) May 22
Lyka Labs Limited, Annual General Meeting, Aug 05, 2022 May 21
Lyka Labs Limited to Report Q4, 2022 Results on May 20, 2022 May 15
Investor sentiment deteriorated over the past week May 11
Investor sentiment improved over the past week Apr 05
High number of new directors Mar 29
These 4 Measures Indicate That Lyka Labs (NSE:LYKALABS) Is Using Debt Reasonably Well Feb 21
Investor sentiment deteriorated over the past week Jan 27
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Jan 21
Investor sentiment improved over the past week Dec 16
High number of new directors Dec 06
Investor sentiment improved over the past week Dec 01
Investor sentiment improved over the past week Nov 17
Statutory Profit Doesn't Reflect How Good Lyka Labs' (NSE:LYKALABS) Earnings Are Nov 05
These 4 Measures Indicate That Lyka Labs (NSE:LYKALABS) Is Using Debt Reasonably Well Nov 03
Second quarter 2022 earnings released: EPS ₹9.90 (vs ₹2.01 loss in 2Q 2021) Nov 01
Investor sentiment improved over the past week Oct 21
Investor sentiment improved over the past week Sep 15
High number of new directors Sep 02
Investor sentiment deteriorated over the past week Aug 16
Full year 2021 earnings released: ₹4.07 loss per share (vs ₹21.29 loss in FY 2020) Jul 10
Lyka Labs Limited Announces Information Regarding Manufacture and Market of Liposomal Amphotericin B Injection Jun 09
Full year 2021 earnings released: ₹4.07 loss per share (vs ₹21.29 loss in FY 2020) Jun 03
Third quarter 2021 earnings released: ₹0.80 loss per share (vs ₹14.50 loss in 3Q 2020) Feb 12
Lyka Labs Limited to Report Q3, 2021 Results on Feb 11, 2021 Feb 05
New 90-day high: ₹25.60 Dec 28
Second quarter 2021 earnings released: ₹2.01 loss per share Nov 07
Lyka Labs Limited Announces Resumption of Operations Sep 19
First quarter earnings released Aug 08
Financial Position Analysis
Short Term Liabilities: LYKALABS's short term assets (₹506.5M) exceed its short term liabilities (₹376.4M).
Long Term Liabilities: LYKALABS's short term assets (₹506.5M) do not cover its long term liabilities (₹508.2M).
Debt to Equity History and Analysis
Debt Level: LYKALABS's net debt to equity ratio (76.9%) is considered high .
Reducing Debt: LYKALABS's debt to equity ratio has reduced from 219.6% to 86.1% over the past 5 years.
Debt Coverage: LYKALABS's debt is not well covered by operating cash flow (3%).
Interest Coverage: LYKALABS's interest payments on its debt are not well covered by EBIT (1.8x coverage).
Discover healthy companies Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
